3 April, 2024

Technology and Innovation Platforms, key elements of Spain’s R&D&I system

The Spanish Technological Platform for Innovative Medicines, led by Farmaindustria, has been promoting public-private collaboration projects in clinical and pre-clinical research since 2005. “Spain currently occupies […]
2 April, 2024


Human papillomavirus is responsible for 95% of cervical tumours. Since 2006, several vaccines have been licensed that can prevent most cases. In Spain, the autonomous communities […]
19 March, 2024

The health sector, essential for the well-being of the population and an economic engine for society The ecosystem of the private healthcare sector transcends the field of healthcare and has an impact on society and on the productive sectors of the […]
7 March, 2024

Spain takes, on average, two years to approve a drug for a minority disease

There are 146 orphan drugs approved by the European Medicines Agency. Spain has only 81 in its catalogue. It has rejected funding for 25 and is […]
5 March, 2024

22% of clinical trials underway in Spain seek new treatments for rare diseases

Research into new drugs for rare diseases has multiplied in recent years. In Spain, industry drives 90% of clinical trials for this type of disease. One […]
13 February, 2024

The Andalusian Regional Government and Farmaindustria will promote R&D&I in health with a special focus on the promotion of clinical trials.

In a press release, the Andalusian Regional Government highlights the joint commitment of both entities to continue advancing in the promotion of R&D&I, following the meeting […]
8 February, 2024

Spain is the country with the highest participation in clinical trials of new drugs in Europe

Of the 1,944 clinical trials authorised in the European Union through the new European Information System, Spanish centres participated in 845, or 43% of the total. […]
6 February, 2024

Europe calls latest cancer drugs “significant progress” for health

The European Medicines Agency has thus identified nine oncology approvals for 2023. The arrival of new treatments is directly linked to the pharmaceutical industry’s commitment to […]
2 February, 2024

The Innovative Medicines Platform sets its roadmap for 2024 with the aim of turning Spain into a major biomedical innovation hub

The Technological Platform for Innovative Medicines – whose Coordination Committee is made up of 10 representatives from the pharmaceutical industry and 10 representatives from public research […]
1 February, 2024

A common catalogue of biomarkers in the National Health System is a great step forward for patients because it improves access to personalised medicine.

Farmaindustria welcomes the presentation by the Ministry of Health of the harmonised catalogue of genetic tests for the whole country. For this catalogue to become a […]
30 January, 2024

Frank R. Lichtenberg, Professor at Columbia University: “Life expectancy of cancer patients in Spain has increased by almost three years in the last decade thanks to the use of innovative drugs”.

The US expert unpacked the data from his study on the relationship between pharmaceutical innovation and cancer mortality in Spain between 1999 and 2016 in a […]
15 January, 2024

FDA approves 55 new drugs in 2023, one of the highest numbers in a decade

Infectious diseases, neurological diseases, type 2 diabetes in children, oncology and cardiac disorders are just some of the areas that benefited from the innovation drive last […]
11 January, 2024

The Distefar team is environmentally conscious and switches from buying single-use plastic bottles to glass bottles.

8 January, 2024

The pharmaceutical industry, a strategic sector for Spain and Europe

“We are the industrial area that invests the most in R&D, a productive and exporting engine”. Developing and producing new medicines for society is both […]
21 December, 2023

Paediatricians join project to boost clinical research in primary care

The working group led by Farmaindustria holds a new meeting, with the participation of two new pharmaceutical companies. The drive for clinical research in Primary […]
19 December, 2023

R&D investment in the pharmaceutical industry reaches 1.4 billion euros in Spain and grows by 10% in just one year

Of the €1.395 billion registered in 2022, 60% was devoted to clinical trial development. One out of every eight euros is already spent on basic and […]
11 December, 2023

“The European Health Data Space is an opportunity to gain greater efficiency in cancer drug research”.

Farmaindustria participates in the Medical Oncology, Haematology and Oncohaematology Pharmacy Congress ‘Building Bridges’, where data management in biomedical research was discussed. “The proposed Regulation for […]
1 December, 2023

“Clinical trials are a hope for patients with rare diseases and already account for 25% of all research done in Spain”.

Farmaindustria’s CEO, Juan Yermo, participates in the conference ‘Towards a Comprehensive European Plan: Spain’s involvement with Rare Diseases’, organised by Feder in the Spanish Congress of […]
27 November, 2023

Boosting clinical research in Primary Care, an opportunity for patients, professionals and the health system

Farmaindustria presents the ‘Guide of good practice recommendations for the promotion of clinical research in Primary Care’, which will bring new treatment opportunities to patients in […]
21 November, 2023

“The European Health Data Space is a unique opportunity that will improve research and innovation for the whole of society.

The director of Farmaindustria’s Research Department participates in a round table on the regulation of this project held at the European Parliament Office in Madrid. “For […]
13 November, 2023

Farmaindustria’s protection of personal data in research is already a benchmark in Europe and is a further incentive to attract clinical trials to Spain.

The Code of Conduct regulating the processing of personal data in clinical trials approved in 2022 makes it easier for companies and researchers to correctly comply […]
2 November, 2023

Medicines for rare diseases already account for 39% of those authorised in Europe, but take more than two years to reach Spain

The director of Farmaindustria’s Access Department, Isabel Pineros, participates in the XVI International Congress on Rare Diseases: “In recent years we have seen great advances in […]
30 October, 2023

New drugs reduce cancer deaths in Spain by almost 30%.

This is demonstrated by a recent study by Professor Frank R. Lichtenberg of Columbia University, which has just been published in the journal Value in Health. […]
24 October, 2023

Precision medicine opens new hopes in breast cancer: 14 targeted therapies authorized since 2018

On World Disease Day, which is celebrated on October 19, Farmaindustria remembers the importance of clinical trials, the previous step for the arrival of innovative treatments […]
17 October, 2023

Farmaindustria launches a proposal to speed up the delivery of innovative medicines to patients in cases where the benefit is most relevant

The document proposes, without the need for a regulatory change, a procedure that would allow the equitable arrival of drugs that meet certain criteria that make […]
11 October, 2023

Urgent measures are needed to encourage innovation and production and enable Europe to make up lost ground.   In a political context with elections called for the European Parliament at the beginning of June 2024 and with Spain holding the presidency of […]
9 October, 2023

Paediatric clinical research advances in Spain driven by collaboration between researchers, healthcare professionals and the pharmaceutical industry

Between 2020 and 2022, 446 clinical trials with children and adolescents were conducted in our country, almost half of them focused on rare diseases and 90.4% […]
4 October, 2023

“Artificial intelligence and technology are driving digital therapies, which benefit not only patients, but the healthcare system and society as a whole”.

In recent years, the number of applications capable of interacting with patients to prevent, manage or treat diseases has increased, and which can also generate data […]
2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research

The 7th Congress of Patients’ Organisations, organised by the POP, analyses the application of the new European Regulation on Clinical Trials. Farmaindustria’s director general, Juan Yermo, […]
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society

The vast majority of them are aimed at modifying the course of the disease, according to an Iqvia report on the future of R&D. In Spain […]
28 January, 2020

Clinical trials, cost savings for the system and innovative therapies for the patient

They are essential to demonstrate the safety of medicines, but they also represent a significant cost savings in the health centers where they are carried out. […]